Loading
Arteriovenous fistula, arteriovenous graft, or central venous catheter — the complete comparison of complication rates, survival, and KDOQI 2019 recommendation hierarchy.
Evidence reviewed & updated: 2026-07 — reflects the latest published trials and guidelines.
The access hierarchy is clear: AV fistula > AV graft > catheter. AVF has the lowest infection and thrombosis rates and longest survival; CVC has the highest complications including central line-associated bloodstream infections (CLABSI) and central venous stenosis. KDOQI 2019 recommends fistula-first with patient-centered planning, and 'catheter last' as a guiding principle.
The Fistula First Breakthrough Initiative (2003) established AVF as the preferred access. KDOQI 2019 reframed this as patient-centered selection: 'select the access that best fits the patient's vascular anatomy, life expectancy, and preferences' — but the evidence hierarchy remains AVF > AVG > CVC.
USRDS data consistently shows: AVF patients have the lowest mortality (adjusted), AVG intermediate, and CVC the highest — with a ~30-50% excess mortality risk attributable to catheter use. CVCs are the single strongest modifiable mortality risk factor in dialysis.
In India, catheter use at HD initiation is 60-70% (vs <30% in the US and <20% in Japan). Late nephrology referral is the primary driver — early referral and access planning are the highest-impact quality improvements available.
Infection: AVF 0.3-0.6 episodes/1000 access-days; AVG 1.0-1.5; CVC (tunneled) 1.5-5.5. Catheter-related bloodstream infections (CRBSI) cause sepsis, metastatic infection (endocarditis, osteomyelitis), and 15-25% mortality per episode.
Thrombosis: AVF 0.2-0.5 events/patient-year; AVG 0.5-1.0 (grafts thrombose more frequently due to neointimal hyperplasia at the venous anastomosis); CVC thrombosis ~10-20% annually.
Other complications: CVCs cause central vein stenosis (affecting future access options), catheter dysfunction/fibrin sheath, and increased hospitalization. AVGs develop pseudoaneurysms and seromas; AVFs can develop steal syndrome, aneurysms, and high-flow complications.
Catheters are appropriate for: urgent dialysis initiation (AKI, late-presenting ESRD), while an AVF matures, failed access without alternatives, and patients with very short life expectancy (palliative care).
Every catheter day is a risk day — guidelines recommend: (1) AVF creation when eGFR <20 mL/min or within 6 months of expected dialysis start, (2) prompt AVF maturation assessment at 6 weeks, (3) CVC removal within 2-4 weeks of successful AVF use.
Center-level strategies to reduce catheter use: structured CKD Stage 4 education (access planning), surgical fast-tracking for access creation, AVF maturation monitoring programs, and audit of catheter prevalence — a NABH-relevant quality indicator.
Track access type at initiation and prevalent access mix — report quarterly. Set targets: catheter prevalence <30%, AVF prevalence >50% (Fistula First benchmarks).
Implement AVF maturation surveillance: physical exam (thrill, bruit) + flow measurement at 6 weeks, with vascular surgery referral for failed maturation (Rule of 6s: flow >600 mL/min, diameter >6mm, depth <6mm).
ZuvFlo's vascular access tracking module documents: access type, creation date, maturation milestones, cannulation history, complications, and catheter dwell days — enabling the data reporting that drives catheter reduction programs.
Advertisement
Access surveillance aims to detect stenosis before thrombosis: monthly access flow (Qa) measurement plus structured phys...
Learn moreBoth hemodialysis (HD) and peritoneal dialysis (PD) provide comparable survival outcomes in most patient populations. Th...
Learn moreOnline hemodiafiltration (HDF) combines diffusive clearance (HD) with convective clearance via ultrafiltration and subst...
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.